Offering HPV Self-Collection in Novel Healthcare Settings to Improve Uptake of Cervical Cancer Screening
- Conditions
- Cervical CarcinomaHuman Papillomavirus InfectionHuman Papillomavirus-Related Cervical Carcinoma
- Registration Number
- NCT07186530
- Lead Sponsor
- Mayo Clinic
- Brief Summary
This clinical trial evaluates whether offering human papillomavirus (HPV) self-collection for cervical cancer screening at Mayo Clinic Express Care clinics improves uptake of cervical cancer screening and receipt of appropriate follow-up care. Cervical cancer is preventable through vaccination, screening, and treatment of pre-cancerous conditions. Despite this, the rates of outdated cervical cancer screening tests are high. Usual care at Mayo Clinic currently includes annual portal or letter communications in the form of scheduled outreach to request scheduling an appointment for cervical cancer screening, as well as reminders from clinicians during clinic appointments. Cervical cancer screening at Mayo Clinic is most often done with a pelvic speculum exam with cervical swabs collected in the office by a clinician. HPV self-collection is Food and Drug Administration-approved and already used in clinical practice, but offering this method of screening in the novel setting of Express Care clinics that have expanded nighttime and weekend hours may improve rates of cervical cancer screening and receipt of appropriate follow-up care.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- NOT_YET_RECRUITING
- Sex
- Female
- Target Recruitment
- 500
- Women ages 30-63 years old receiving primary care with a provider at Mayo Clinic in Rochester or Mayo Family Clinic Kasson and who self-identify as asymptomatic (i.e., no pelvic pain, abnormal vaginal bleeding or abnormal vaginal discharge)
- Qualify for average risk cervical cancer screening per United States Preventive Services Task Force (USPSTF) guidelines but are overdue by >= 1 year, including those who have never been screened
- Must have an active Patient Online Services account (patient portal), approval for research contact status in portal/Epic and documentation of Minnesota (MN) research authorization, and health insurance coverage
- History of hysterectomy
- Cervical cancer
- Cervical intraepithelial neoplasia (CIN) 2-3
- In utero diethylstilbestrol (DES) exposure
- HIV+
- Use of chronic immunosuppressant medication
- Known to be pregnant
- Medicare-covered women are NOT eligible as Medicare does not cover primary HPV testing by clinician-collection or self-collection [related to outdated Centers for Medicare & Medicaid Services (CMS) cervical cancer screening coverage rules for Medicare that date back to 2015, 3 years before primary HPV screening was endorsed by USPSTF]
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Cervical cancer screening test Up to 6 months from trial enrollment Assessed by the number of participants who complete cervical cancer screening collection from invitation to complete a self-collected vaginal swab for HPV testing at Mayo Clinic Express Care clinics compared to the number of participants who complete screening with a clinician-collected cervical swab or self-collected vaginal swab at a primary care office.
- Secondary Outcome Measures
Name Time Method Follow-up of abnormal results Up to 6 months from date of test Assessed by the number of participants who complete follow-up for abnormal results obtained by self-collection or clinician-collection.
Trial Locations
- Locations (2)
Mayo Family Clinic Kasson
🇺🇸Kasson, Minnesota, United States
Mayo Clinic in Rochester
🇺🇸Rochester, Minnesota, United States
Mayo Family Clinic Kasson🇺🇸Kasson, Minnesota, United StatesJulie MaxsonContact507-266-0284maxson.julie@mayo.eduKathy L. MacLaughlin, PhDPrincipal Investigator